Valentyn OksenychEditorial on the Research Topic
Plasticity of immune cells in tumor microenvironment
Immune cells, cancer-associated fibroblast, and tumor cells, together with the extracellular matrix and factors, form a tumor microenvironment (1). Tumor microenvironment modulates various cancer therapy options and can be used for a cancer treatment prognosis. While cancer-associated fibroblasts rather support tumor cells, presence of immune cells differs between individual tumors even of the same type. For example, tumors with a significant proportion of immune cells (“hot tumors”) are more likely to be cured than tumors with less immune cells but more cancer cells and cancer-associated fibroblasts (“cold tumors”) (2). Cancer-associated fibroblasts and tumor cells can produce factors inhibiting immune cells (T lymphocytes, natural killer cells, dendritic cells, macrophages) in the tumor microenvironment (1, 3). Cytotoxic T cells, natural killers, dendritic cells, and certain types of macrophages contribute to eliminating tumors. The current Research Topic’s purpose was to collect publications on the immune cells in the context of the tumor microenvironment.
In an original research article, Chen et al. focused on the role of macrophages in glioma cancer. Glioma is a cancer type that originates in spinal cord or brain from the glial cells that normally surround nerve cells and support their functions. Gliomas are a leading cause of cancer death around the world. Surgery, chemotherapy, and radiation therapy can help treat gliomas, but the overall survival for low-grade glioma is nine years, and for glioblastoma it is thirteen months (4). This bioinformatic-based study examined the prognostic and predictive value of antigen presentation machinery (APM) signature (5) in gliomas. This signature showed promising results in predicting survival and tumorigenic factors in glioma patients. The signature-based risk score was independently validated in three external cohorts and was able to predict immunotherapy response. Furthermore, the risk score-derived calreticulin (a product of CALR gene) (6) was found to mediate the invasion and polarization of macrophages. In conclusion, APM signature-based risk score can help improve the clinical management of gliomas.
In another original research article, Du et al. presented their finding on the metabolic signatures and antitumor immune response in the context of head and neck squamous cell carcinoma. Immune checkpoint inhibitor-based therapy, such as related to anti-programmed death 1 (PD1), anti-programmed death-ligand 1 (PD-L1), and anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4), has improved cancer survival rates (7, 8). In head and neck squamous cell carcinoma (HNSCC), recurrent or metastatic patients have also seen significant survival benefits from this therapy (9). Here, a metabolic-related gene prognostic index (MRGPI) was constructed to predict outcomes and immunotherapy response in head and neck squamous cell carcinoma. Seven genes were identified from the TCGA and GEO datasets (ADA, ACADL, AGPAT4, AMY2B, CKM, HPRT1, and PLA2G2D), and patients with a low MRGPI score had better overall survival than those with a high score. Low MRGPI scores were associated with lower metabolic activities, active antitumor immunity, and more benefit from immunotherapy. High MRGPI scores correlated with higher metabolic activities, higher TP53 mutation rate, lower immune response, and less benefit from immunotherapy. In conclusion, MRGPI is a promising indicator for distinguishing the HNSCC prognosis, metabolic, molecular, and immune phenotype and predict immunotherapy benefits.
In the third original research article, Wang et al. focused on the tumor-secreted lactate and found that it modulates glioblastoma progression by modulating response to interferon-gamma by tumor, cytotoxic T cells, macrophages and microglia. Glioblastoma is one of the most aggressive types of cancer, and it originates in brain. This study examined the relationship between lactate and glioblastoma. Over 1400 glioblastoma samples were analyzed and the results were validated with another set of data. Lactate was found to predict glioblastoma progression, modulate the tumor immune landscape, and influence cytotoxic T cells and the tumor’s response to interferon-gamma. Machine learning algorithms and cell-cell interaction suggested that cytotoxic T cells and microglial cells may communicate with the tumor through lactate. Based on the cluster model, potential compounds which may offer new treatments were also predicted. Overall, lactate contributes to the immune suppressive microenvironment in the context of glioblastoma.
In the review article, Guo et al. focus on the immune evasion and drug resistance mediated by USP22 in cancer. Immune evasion is the way cancer cells escape and hide from the immune system, which otherwise recognizes and eliminates them. USP22 is a ubiquitin-specific peptidase 22 protein associated with various pathological conditions (10, 11). USP22 is a deubiquitinase involved in various cancer development-related cellular processes, such as cell cycle arrest, cell proliferation, apoptosis, invasion, metastasis, and immunity. It also affects proteome, may stabilize programmed death ligand 1 (PD-L1), and regulates T-cell infiltration into tumors. USP22 was found to positively regulate stable FOXP3 expression and reduce tumor volume when ablated in Tregs. This suggests that USP22 may regulate tumor resistance to immunotherapy. This article summarizes the biological functions of USP22 in multiple signal transduction pathways during tumorigenesis, immune evasion, and drug resistance, and proposes combining USP22 with chemotherapeutic, targeted, and immunosuppressive drugs in cancer treatment.
In the second review article, Zhao et al. discuss targeting immune cells for gastric cancer therapies. Gastric cancer (GC) is a malignancy with a high mortality rate. Immunotherapy has brought survival benefits to GC patients, offering durable responses and lower toxicity than traditional therapies. This review introduces the roles of each immune cell in the GC tumor microenvironment and summarizes the current immunotherapy strategies, such as immune checkpoint inhibitors, adoptive cell therapy (ACT), dendritic cell vaccines, reduction of M2 tumor-associated macrophages (TAMs) and N2 tumor-associated neutrophils (TANs), and reprogramming of TAMs and TANs. The most widely used therapies are PD-1/PD-L1 and CTLA-4 antibodies and CAR-T in ACT, and these strategies have shown anti-tumor efficacy in solid and hematological tumors. Targeting other immune cells provides a new direction for the immunotherapy of GC, and some of these strategies have entered clinical trials.
Overall, based on the articles on the Research Topic, there are two major directions of cancer therapy development, which will likely be relevant during the next decade. First is a wider usage of methods engaging the immune system to fight cancer via various immunotherapeutic protocols. Second is a broader usage of information technologies, including advanced methods of statistics, machine learning, and artificial intelligence approaches.
Author contributions
The author confirms being the sole contributor of this work and has approved it for publication.
Conflict of interest
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Ragunathan K, Upfold NLE, Oksenych V. Interaction between fibroblasts and immune cells following DNA damage induced by ionizing radiation. Int J Mol Sci (2020) 21(22):1–15. doi: 10.3390/ijms21228635
2. Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics (2021) 11(11):5365–86. doi: 10.7150/thno.58390
3. Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science (2010) 330(6005):827–30. doi: 10.1126/science.1195300
4. Zhang H, Wang R, Yu Y, Liu J, Lou T, Fan F, et al. Glioblastoma treatment modalities besides surgery. J Cancer (2019) 10(20):4793–806. doi: 10.7150/jca.32475
5. Wang S, He Z, Wang X, Li H, Liu XS, et al. Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction. Elife (2019) 8:1–20. doi: 10.7554/eLife.49020
6. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med (2013) 369(25):2391–405. doi: 10.1056/NEJMoa1312542
7. Baas P, Scherpereel A, Nowak AK, Fijimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial. Lancet (2021) 397(10272):375–86. doi: 10.1016/S0140-6736(20)32714-8
8. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob N, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med (2019) 381(16):1535–46. doi: 10.1056/NEJMoa1910836
9. Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial. Lancet Oncol (2016) 17(7):956–65. doi: 10.1016/S1470-2045(16)30066-3
10. Chipumuro E, Henriksen MA. The ubiquitin hydrolase USP22 contributes to 3'-end processing of JAK-STAT-inducible genes. FASEB J (2012) 26(2):842–54. doi: 10.1096/fj.11-189498
Keywords: tumor microenvironment, glioblastoma, glioma, USP22, gastric cancer
Citation: Oksenych V (2023) Editorial: Plasticity of immune cells in tumor microenvironment. Front. Oncol. 13:1160961. doi: 10.3389/fonc.2023.1160961
Received: 07 February 2023; Accepted: 09 February 2023;
Published: 17 February 2023.
Edited and Reviewed by:
Udo S Gaipl, University Hospital Erlangen, GermanyCopyright © 2023 Oksenych. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Valentyn Oksenych, valentyn.oksenych@medisin.uio.no